Literature DB >> 35492778

Conversion of N-acyl amidines to amidoximes: a convenient synthetic approach to molnupiravir (EIDD-2801) from ribose.

Ajaz Ahmed1,2, Qazi Naveed Ahmed1,2, Debaraj Mukherjee1,2.   

Abstract

An efficient method is described for the preparation of molnupiravir (EIDD-2801) an antiviral agent via regioselective conversion of an N-acyl-nucleoside intermediate, generated through stereo and regioselective glycosylation of protected ribose and N 4-acetyl cytosine, to an amidoxime. This method avoids use of expensive starting materials, enzymes, complex reagents, and cumbersome purification procedures. This journal is © The Royal Society of Chemistry.

Entities:  

Year:  2021        PMID: 35492778      PMCID: PMC9043332          DOI: 10.1039/d1ra06912h

Source DB:  PubMed          Journal:  RSC Adv        ISSN: 2046-2069            Impact factor:   4.036


Introduction

Amidoximes, having both hydroxylamino and imino groups at the same carbon atom, and their O-substituted derivatives form a unique class of pharmaceutical products with varied activities such as anti-bacterial, anti-tuberculosis, insecticidal, antiviral etc.[1] A number of amidoximes are currently in use as drugs, or are undergoing clinical trials. Molnupiravir, also known as EIDD-2801 and MK-4482, is one such compound being studied in late-stage clinical trials for combating infections caused by COVID-19, and acts by disrupting RNA synthesis.[2-5] Its advantages over remdesivir, the other drug in use, are oral bioavailability and structural simplicity allowing its easier manufacture.[6] The reported synthetic route for molnupiravir disclosed by the original developers consists of a five-step synthesis starting from uridine.[7] The method suffers from low yield (ca. 17%) and the use of an inefficient (yield 29%) triazole insertion step (Scheme 1A). In a revised route with an improved yield reported by Kappe, Dallinger, and co-workers, the triazole insertion was introduced in the first step of a modified procedure.[8] Snead and co-workers published another route to molnupiravir with 60% yield starting with cytidine and using acetonide protection, esterfication, hydroxyamination and acetonide deprotection.[9] The same group also published two different two-step routes from cytidine, where selective enzymatic esterification of the primary alcohol replaced the diol protection/deprotection sequence.[10,11] However, the drawbacks include use of expensive oxime ester, need for immobilized enzyme in large amounts, formation of diester (both at O- and NHO-) along with the desired monoester, and the necessity for removal of O-ester during transamination (Scheme 1B).
Scheme 1

Different approaches to Molnupiravir (A) Innovator synthetic method, (B) David R Snead method, (C) our method and hypothesis.

Merck & Co (USA) carried out an elegant enzymatic synthesis starting from ribose and uracil.[12] However it entails the use of cocktails of costly enzymes and buffers used in the glycosylation step, while the high water solubility of the final product makes its isolation tricky. Our interest in nucleoside synthesis[13],[18] led us to devise an alternative to overcome the shortcomings. We envisaged that the amino group at C-4 might get substituted by hydroxylamine to form 4-hydroxylamino derivative (Scheme 1C). In the case of cytidine, this exchange may be facilitated by the presence of an electron withdrawing group (perhaps an acyl) on the nitrogen at C-4 and thereby N-acyl cytidine can be converted directly to amidoximes under mild conditions by the removal of corresponding amides. For this, our initial task was to synthesize N-acyl protected cytidine from the free base and thereafter attempt to selectively convert it to the 4-hydroxylamine derivative under controlled conditions to avoid deprotection of the ester at the primary hydroxyl group (Scheme 1C). The advantages of the envisaged process will include (a) avoiding chlorinating solvents like POCl3, and (b) better yield in the coupling step as compared to uracil. This would also present an alternative strategy to EIDD-2801, employing ribose and cytosine rather than cytidine. Thus, we focused on the development of an efficient route to access N-acyl cytidine derivative for a regio and stereo selective glycosylation.

Results and discussion

We initiated the process by synthesising the key intermediate 2 from commercially available d-(−)-ribose. It could be locked in its furanoid form employing an HCl mediated acetonide protection procedure,[14] followed by benzoylation of the free hydroxyl group of 1 with benzoyl chloride in pyridine at ambient temperature (Scheme 2). Hydrolysis of 2 with trifluoroacetic acid and water (9 : 1) resulted in the removal of the acetonide group at 2,3-position and the methyl group from anomeric hydroxy in a single step. Subsequent acetylation with acetic anhydride in pyridine furnished 1,2,3-tri-O-acetyl-5-benzoyl-β-d-ribofuranose 3 in 90% overall yield (Scheme 2).
Scheme 2

Access of furanoid ribose as donor.

The key step involved in the synthesis of molnupiravir is a stereo and regioselective glycosylation, where coupling of nucleobases 4a–c with 3 is desired. Silylation of nucleobases with hexamethyldisilazane (HMDS) in catalytic amount of TMSOTf prior to coupling with sugar donors is well known Silyl Hilbert–Johnson reaction which is reported mostly for the synthesis of uridine derivatives.[15] But, mostly cytidine is obtained from uridine after a series of steps which involves chlorination with POCl3 and substituent installation of 1,2,4-triazole to get amine with the treatment of hydroxylamine[16] (Scheme 3A). For direct access of cytidine Raffaele et al. reported microwave accelerated glycosylation approach from N-benzoyl cytosine with 50% yield[17] (Scheme 3B), So in order to improve the yield further optimization of reaction was needed. Therefore we firstly treated N-protected cytosine 4a with HMDS and TMSOTf (catalytic amount) in acetonitrile at 80 °C for 1 h, then added 3 and SnCl4 and stirred at the same temperature only to end up with a mixture of regioisomers of cytidine derivatives in low yield (ESI,†Table 1, entry 1).
Scheme 3

Literature reports for the synthesis of cytidine, (A) Vorbruggen glycosylation method, (B) B. Raffaele microwave assisted method and (C) our method.

Optimization of the reaction conditionsa

EntryCytosinePromotor (equiv.)SolventTemp. (°C)Time (h)Yieldb (%)
14aSnCl4 (1.0)ACN801220
24aSnCl4 (1.0)DCM80528
34aSnCl4 (1.0)DCE80354
44aSnCl4 (1.0)DMF8035
54aSnCl4 (1.0)1,4 dioxane80315
64bSnCl4 (1.0)DCE80364
74cSnCl4 (1.0)DCE80362
84bSnCl4 (1.0)DCE60370
94bSnCl4 (1.0)DCE40568
104bTMSOTf (1.0)DCE60348
114bZnCl2 (1.0)DCE40318
124bTiCl4 (1.0)DCE40311
134bSnCl4 (0.5)DCE60352
144bSnCl4 (2.0)DCE60370

Reaction conditions: 1 equiv. of N-acetyl cytosine 4b, HMDS (1.5 equiv.) and TMSOTf (0.1 equiv.) at 80 °C for 1 h followed by cooling the reaction mixture down to 60 °C before the addition of 0.5 equiv. of 3 and 1 equiv. SnCl4 and allowing the reaction mixture to stir for 3 h.

Isolated yield.

Reaction conditions: 1 equiv. of N-acetyl cytosine 4b, HMDS (1.5 equiv.) and TMSOTf (0.1 equiv.) at 80 °C for 1 h followed by cooling the reaction mixture down to 60 °C before the addition of 0.5 equiv. of 3 and 1 equiv. SnCl4 and allowing the reaction mixture to stir for 3 h. Isolated yield. To increase the yield and regioselectivity we screened different solvents like DCM, DCE, DMF, and 1,4-dioxane. This showed that DCE was the best solvent to obtain a high yield of the product but regioselectivity remained a concern (ESI,† Table 1, entries 2–5). In order to improve this, we planned to perform the glycosylation with N-masked cytosine derivatives. To our delight, replacing cytosine with N-acetyl cytosine 4b and N-benzoyl cytosine 4c ensured the desired regioselectivity (ESI,†Table 1, entries 6–7). Decreasing the temperature from 80 °C to 60 °C resulted in still more increase in the selectivity and yield of the product, but further lowering to 40 °C was not helpful (ESI,†Table 1, entries 8–9). Also, using promoters other than SnCl4 gave unsatisfactory results (ESI,†Table 1, entries 10–12). Although decreased proportion of promoter affects the yield of the product, but increase beyond the stoichiometric amount did not improve the yield (ESI,†Table 1, entry 13–14). Consolidating the outcome of our optimization study, it appeared that using 1 equiv. of N-acetyl cytosine 4b with HMDS (1.5 equiv.) and TMSOTf (0.1 equiv.) at 80 °C for 1 h followed by cooling the reaction mixture down to 60 °C before the addition of 0.5 equiv. of 3 and 1 equiv. SnCl4 and allowing the reaction mixture to stir for 3 h at the same temperature delivers the desired nucleoside in good yield (Scheme 3). In order to remove all the protecting groups, 5 was exposed to ammonia (20%) in methanol at 50 °C which resulted in deprotection of N-acetyl, O-acetyl and O-benzoyl groups within 5 h to deliver cytidine 6 (Scheme 3). To selectively introduce the isobutyl ester at the 5′-hydroxy and 4-amino positions of 6, the other hydroxy groups at 2′ and 3′ needed to be protected first. Using the reported conditions for the acetonide protection (5 mol% H2SO4 in acetone),[15] about 20% conversion to the desired acetonide 7 took place. The use of Iodine (5 mol%) in place of H2SO4 did not significantly improve the outcome. However addition of 2 equiv. of 2,2-dimethoxypropane (DMP) showed an increase in conversion. The best results were obtained by changing the solvent from acetone to MeCN, which in combination with the use of DMP smoothly effected a 94% conversion to 7 (Scheme 3). Next, attempting the esterification of both 5′-hydroxy and 4-amino positions of 7 according to the reported method[14] revealed that 2 equiv. of isobutyric anhydride produced a mixture of mono and diacylated products. In order to reach full conversion of 7 to 8, use of 3.0 equiv. of anhydride at ambient temperature was found to work best (Scheme 3). The most crucial step involved in the process was conversion of amidine amino to hydroxylamino without affecting the primary O-ester group. To achieve this, we used different hydroxyl amine derivatives in the presence of bases, varying temperature as well as time. Thus heating 8 with 2 molar hydroxylamine solution in the presence of sodium acetate in isopropanol at 50 °C caused hydrolysis of both O-ester and amide groups to form 9b (Table 2, entry 1). Replacement of hydroxylamine solution with hydroxylamine hydrochloride resulted in the formation of the N-hydroxylated product 9a along with 9b (Table 2, entry 2). In order to increase the yield of the desired product, isopropanol was replaced with water to derive satisfactory results (Table 2, entry 3). Yield of the desired product was found better at the boiling point of water instead of 50 °C (Table 2, entry 4). Also time played a critical role on the outcome of the reaction. For instance, lowering of the time period of the reaction from 12 h to 40 min increased the yield of the desired product (Table 2, entry 4–5). To check the role of NaOAc, a reaction in the absence of it was performed only to get 9b in 20% yield (Table 2, entry 6). Replacement of NaOAc with other bases failed to improve the yield (Table 2, entries 7–11). On decreasing the proportion of hydroxylamine hydrochloride, the yield of the product was found to be decreased whereas an increase had little influence (Table 2, entries 12–13). Consolidating these outcomes, employing acetonide diester 8 (1 equiv.), hydroxyl amine hydrochloride (4.0 equiv.), and sodium acetate (2.5 equiv.) in water at 100 °C for 40 min proved to be the best condition for obtaining the desired product 9a (Scheme 3). Deprotection of the acetonide group of 8 to EIDD-2801 has been described to proceed in H2SO4 in combination with iPrOH as solvent. However, we failed to achieve satisfactory conversion under the reported conditions. But screening of different acids like formic acid, acetic acid, and trifluoroacetic acid (TFA) for different time periods revealed that an aqueous solution of TFA worked best, effecting the highest conversion (90%) to EIDD-2801 10 in 1 h at room temperature (Scheme 3). Finally, keeping in mind the requirement of large amount of drug and the availability of cytidine as a cheap raw material, we have carried out the 2-step synthesis of EIDD-2801 from cytidine 6, one of the intermediates in our synthetic route, in 62% overall yield (Scheme 4).

Standarization of reaction conditionsa

EntryHydroxyl-amine deriv. (4 equiv.)Base (2.5 equiv.)SolventTime (h)Yieldb9a : 9b
1NH2OH (2 M)NaOAciPrOH120 : 50
2NH2OH·HClNaOAciPrOH1210 : 30
3NH2OH·HClNaOAcH2O1230 : 20
4NH2OH·HClNaOAcH2O250 : 15
5 NH 2 OH·HCl NaOAc H 2 O 40 min 88 : 0
6NH2OH·HClH2O40 min0 : 20
7NH2OH·HClNa2CO3H2O100 : 15
8NH2OH·HClNaHCO3H2O100 : 23
9NH2OH·HClCs2CO3H2O100 : 18
10NH2OH·HClKOAcH2O140 : 10
11NH2OH·HClCa(OAc)2H2O123 : 14
12NH2OH·HCl (2.0 equiv.)NaOAcH2O157 : 12
13NH2OH·HCl (6.0 equiv.)NaOAcH2O175 : 0

Reaction conditions: 1 equiv. acetonide diester 8, 4.0 equiv. (except entry 12, 13) hydroxyl amine hydrochloride (2 M NH2OH for entry 1), and 2.5 equiv. base in water (iPrOH for entry 1,2) at 100 °C (50 °C for entry 1–3) for specified time.

Isolated yield.

Scheme 4

Diester synthesis and regioselective conversion of N-hydroxylaton.

Reaction conditions: 1 equiv. acetonide diester 8, 4.0 equiv. (except entry 12, 13) hydroxyl amine hydrochloride (2 M NH2OH for entry 1), and 2.5 equiv. base in water (iPrOH for entry 1,2) at 100 °C (50 °C for entry 1–3) for specified time. Isolated yield.

Conclusions

In conclusion, we have developed an efficient process for the synthesis of molnupiravir starting with cheaper commercially available ribose and N4-acetyl cytosine, which ensures stereo and regioselective glycosylation and regioselective conversion of N-acyl to hydroxylamino derivative in good to excellent yields. Other N-hydroxy cytidine derivatives could also be synthesized by employing this method.

Conflicts of interest

There are no conflicts to declare.
  13 in total

1.  A concise route to MK-4482 (EIDD-2801) from cytidine.

Authors:  N Vasudevan; Grace P Ahlqvist; Catherine P McGeough; Dinesh J Paymode; Flavio S P Cardoso; Tobias Lucas; Jule-Phillip Dietz; Till Opatz; Timothy F Jamison; Frank B Gupton; David R Snead
Journal:  Chem Commun (Camb)       Date:  2020-10-08       Impact factor: 6.222

2.  High-throughput five minute microwave accelerated glycosylation approach to the synthesis of nucleoside libraries.

Authors:  Brett C Bookser; Nicholas B Raffaele
Journal:  J Org Chem       Date:  2007-01-05       Impact factor: 4.354

3.  β-d-N 4-Hydroxycytidine Is a Potent Anti-alphavirus Compound That Induces a High Level of Mutations in the Viral Genome.

Authors:  Nadya Urakova; Valeriya Kuznetsova; David K Crossman; Arpine Sokratian; David B Guthrie; Alexander A Kolykhalov; Mark A Lockwood; Michael G Natchus; Michael R Crowley; George R Painter; Elena I Frolova; Ilya Frolov
Journal:  J Virol       Date:  2018-01-17       Impact factor: 5.103

4.  Pd-Catalyzed Regio- and Stereoselective C-Nucleoside Synthesis from Unactivated Uracils and Pyranoid Glycals.

Authors:  Faheem Rasool; Debaraj Mukherjee
Journal:  Org Lett       Date:  2017-09-06       Impact factor: 6.005

Review 5.  Recent developments in the chemistry and in the biological applications of amidoximes.

Authors:  K C Fylaktakidou; D J Hadjipavlou-Litina; K E Litinas; E A Varella; D N Nicolaides
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

6.  An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice.

Authors:  Timothy P Sheahan; Amy C Sims; Shuntai Zhou; Rachel L Graham; Andrea J Pruijssers; Maria L Agostini; Sarah R Leist; Alexandra Schäfer; Kenneth H Dinnon; Laura J Stevens; James D Chappell; Xiaotao Lu; Tia M Hughes; Amelia S George; Collin S Hill; Stephanie A Montgomery; Ariane J Brown; Gregory R Bluemling; Michael G Natchus; Manohar Saindane; Alexander A Kolykhalov; George Painter; Jennifer Harcourt; Azaibi Tamin; Natalie J Thornburg; Ronald Swanstrom; Mark R Denison; Ralph S Baric
Journal:  Sci Transl Med       Date:  2020-04-06       Impact factor: 17.956

7.  Small-Molecule Antiviral β-d-N 4-Hydroxycytidine Inhibits a Proofreading-Intact Coronavirus with a High Genetic Barrier to Resistance.

Authors:  Maria L Agostini; Andrea J Pruijssers; James D Chappell; Jennifer Gribble; Xiaotao Lu; Erica L Andres; Gregory R Bluemling; Mark A Lockwood; Timothy P Sheahan; Amy C Sims; Michael G Natchus; Manohar Saindane; Alexander A Kolykhalov; George R Painter; Ralph S Baric; Mark R Denison
Journal:  J Virol       Date:  2019-11-26       Impact factor: 5.103

8.  Progress Toward a Large-Scale Synthesis of Molnupiravir (MK-4482, EIDD-2801) from Cytidine.

Authors:  Grace P Ahlqvist; Catherine P McGeough; Chris Senanayake; Joseph D Armstrong; Ajay Yadaw; Sarabindu Roy; Saeed Ahmad; David R Snead; Timothy F Jamison
Journal:  ACS Omega       Date:  2021-04-08

9.  Engineered Ribosyl-1-Kinase Enables Concise Synthesis of Molnupiravir, an Antiviral for COVID-19.

Authors:  John A McIntosh; Tamas Benkovics; Steven M Silverman; Mark A Huffman; Jongrock Kong; Peter E Maligres; Tetsuji Itoh; Hao Yang; Deeptak Verma; Weilan Pan; Hsing-I Ho; Jonathan Vroom; Anders M Knight; Jessica A Hurtak; Artis Klapars; Anna Fryszkowska; William J Morris; Neil A Strotman; Grant S Murphy; Kevin M Maloney; Patrick S Fier
Journal:  ACS Cent Sci       Date:  2021-10-29       Impact factor: 14.553

Review 10.  Toward a Practical, Nonenzymatic Process for Investigational COVID-19 Antiviral Molnupiravir from Cytidine: Supply-Centered Synthesis.

Authors:  Vijayagopal Gopalsamuthiram; Appasaheb L Kadam; Jeffrey K Noble; David R Snead; Corshai Williams; Timothy F Jamison; Chris Senanayake; Ajay K Yadaw; Sarabindu Roy; Gopal Sirasani; B Frank Gupton; Justina Burns; Daniel W Cook; Rodger W Stringham; Saeed Ahmad; Rudy Krack
Journal:  Org Process Res Dev       Date:  2021-12-09       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.